Cargando…

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue attributed to variable BCMA expression, BCMA downregulation, and heterogeneity of tumor antige...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Jieyun, Li, Zhenyu, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240779/ https://www.ncbi.nlm.nih.gov/pubmed/37277826 http://dx.doi.org/10.1186/s13045-023-01461-1

Ejemplares similares

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)

Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
por: Yin, Xuejiao, et al.
Publicado: (2023)

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
por: Tan, Jiaxiong, et al.
Publicado: (2023)

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
por: Xu, Jieyu, et al.
Publicado: (2023)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
por: Huang, Qiusha, et al.
Publicado: (2023)

Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
por: DiNardo, Katherine W., et al.
Publicado: (2023)

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
por: Wang, Chaoyu, et al.
Publicado: (2023)

Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
por: Chen, Yiyin, et al.
Publicado: (2023)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
por: Guo, Ruiting, et al.
Publicado: (2022)

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
por: Wang, Ji-nuo, et al.
Publicado: (2022)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Recent advances in myelodysplasia: update from 2011 ASH annual meeting
por: Liu, Delong
Publicado: (2012)

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
por: Lee, Holly, et al.
Publicado: (2023)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
por: Wang, Andrew, et al.
Publicado: (2023)

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting
por: Zhang, Kejie, et al.
Publicado: (2016)

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
por: Lin, Zhijuan, et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
por: Hou, Jing-Zhou, et al.
Publicado: (2021)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy
por: Berger, Peer Andre, et al.
Publicado: (2022)

ASENT 2022 Annual Meeting
Publicado: (2022)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020
Publicado: (2021)

2022 ASCB Annual Meeting abstracts
Publicado: (2023)

SCTS Annual Meeting 2022 Abstracts
Publicado: (2023)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting
por: Li, Yangqiu
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t7vjo8203jk9nrj52goo3gj3g4